Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Alexander M. Labeit, MDPhD, Mhairi Copland, BSc (Hons) MB ChB PhDFRCP FRCPath, Leanne M. Cork, BSc (Hons), Corinne A. Hedgley, BSc (Hons), Letizia Foroni, MDPhDFRCPath, Wendy L. Osborne, MBBS (Hons) MRCP FRCPath, Gemma Gills, MSc BSc (Hons), Jane F. Apperley, MD, Tessa L. Holyoake, MDPhD, Ruth V. Bescoby, MSc BSc, Christopher Pocock, Thomas Zwingers, MSc, Philippa Burnell, Jenny L. Byrne, PhD, John H. McCullough, John M. Goldman, DM FRCP FRCPath, Richard E. Clark, MD, Stephen G. O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath

Blood (2015) 126 (23): 4024.

https://doi.org/10.1182/blood.V126.23.4024.4024

Published: 2015

Journal Articles

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Stephen G O'Brien, BSc (Hons) PhD MBChB FRCP MRCPath, Corinne Hedgley, BSc, Sarah Adams, BSc MSc, Letizia Foroni, MDPhD, Jane F. Apperley, MD, Tessa L Holyoake, MDPhDFRSE FMedSci, Christopher Pocock, MD PhD, Jenny L Byrne, MB ChB PhDFRCP FRCPath, Lynn Margaret Seeley, MSc RN NDN, Wendy L Osborne, MBBS(Hons) MRCP FRCPath, John M Goldman, DM, Mhairi Copland, BSc PhDFRCP FRCPath, Richard E Clark, MA, MD

Blood (2014) 124 (21): 517.

https://doi.org/10.1182/blood.V124.21.517.517

Published: 2014

Journal Articles

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Blood (2013) 122 (21): 4007.

https://doi.org/10.1182/blood.V122.21.4007.4007

Published: 2013

Journal Articles

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Blood (2013) 122 (21): 1496.

https://doi.org/10.1182/blood.V122.21.1496.1496

Published: 2013

Journal Articles

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Blood (2013) 122 (21): 652.

https://doi.org/10.1182/blood.V122.21.652.652

Published: 2013

Journal Articles

2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection

Blood (2010) 116 (21): 677.

https://doi.org/10.1182/blood.V116.21.677.677

Published: 2010

Journal Articles

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Ian H Gabriel, MD, David Marin, MD, FRCP, Shahzad Ahmad, Mr, Letizia Foroni, Hugues de Lavallade, MD, Richard E. Clark, MBBS, MD, FRCP, FRCPath, Stephen O'Brien, PhD, Ruhena Sergeant, Dragana Milojkovic, MD, Marco Bua, Abdullah Alsuliman, Ahmad Khoder, Dr, Kate Stringaris, MD, MRCP, FRCPath, Nichola Cooper, MD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane F. Apperley, Katayoun Rezvani, MD, PhD

Blood (2010) 116 (21): 888.

https://doi.org/10.1182/blood.V116.21.888.888

Published: 2010

Journal Articles

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Amr R Ibrahim, Dragana Milojkovic, Marco Bua, Jamshid S Khorshad, Richard Szydlo, Lina Eliasson, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 3414.

https://doi.org/10.1182/blood.V116.21.3414.3414

Published: 2010

Journal Articles

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

Amr R Ibrahim, Marco Bua, Jamshid S Khorshad, Dragana Milojkovic, Lina Eliasson, Richard Szydlo, Letizia Foroni, MD, PhD, Alistair Reid, Hugues de Lavallade, Katayoun Rezvani, MD, PhD, John M. Goldman, DM, FRCP, FRCPath, FMedSci, Jane Apperley, MBChB, FRCP, FRCPath, David Marin, MD, FRCP

Blood (2010) 116 (21): 2274.

https://doi.org/10.1182/blood.V116.21.2274.2274

Published: 2010

Journal Articles

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.

Alexandra Bazeos, David Marin, Gareth Gerrard, PhD, Richard Szydlo, Dragana Milojkovic, MD, Alistair Reid, Hugues de Lavallade, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FCRP, FRCPath, Letizia Foroni, Jamshid Sorouri Khorashad, MD

Blood (2009) 114 (22): 3248.

https://doi.org/10.1182/blood.V114.22.3248.3248

Published: 2009

Journal Articles

Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase.

John M. Goldman, DM, FRCP, FRCPath, Navneet S. Majhail, MD, MS, John P. Klein, PhD, Zhiwei Wang, MS, Kathleen A. Sobocinski, MS, Mukta Arora, MD, Mary M. Horowitz, MD, MS, J. Douglas Rizzo, MD, MS

Blood (2009) 114 (22): 3321.

https://doi.org/10.1182/blood.V114.22.3321.3321

Published: 2009

Journal Articles

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Michael Deininger, MD, PhD, Stephen G O'Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FCRP, Andreas Hochhaus, MD, Timothy P. Hughes, MD, MBBS, Jerald P. Radich, MD, Alan K. Hatfield, MD, FACP, Manisha Mone, PhD, Jeiry Filian, John Reynolds, Insa Gathmann, Richard A. Larson, MD, Brian J. Druker, MD

Blood (2009) 114 (22): 1126.

https://doi.org/10.1182/blood.V114.22.1126.1126

Published: 2009

Journal Articles

T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.

Hugues de Lavallade, MD, MsC, Melanie Hart, PhD, Ian H Gabriel, Dr, Peter Kelleher, MD, PhD, Abdullah Alsuliman, PhD, Ahmad Khoder, MD, Dragana Milojkovic, MD, Letizia Foroni, Marco Bua, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FCRP, David Marin, MD, Katayoun Rezvani, MD, PhD

Blood (2009) 114 (22): 2214.

https://doi.org/10.1182/blood.V114.22.2214.2214

Published: 2009

Journal Articles

Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis

Franck E Nicolini, MD, PhD, Giovanni Martinelli, Dong-Wook Kim, MD, PhD, Andreas Hochhaus, MD, Michael J. Mauro, MD, Jorge Cortes, MD, Charles Chuah, MBChB, MRCP, MD, Inge Dufva, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, Fumiharu Yagasaki, MD, Jay Pearson, PhD, Senaka Peter, MBA, Cesar Sanz Rodriguez, MD, Frank Giles, MD, John M Goldman, DM, FCRP, FRCPath, Wei Zhou, PhD

Blood (2008) 112 (11): 188.

https://doi.org/10.1182/blood.V112.11.188.188

Published: 2008

Journal Articles

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

Jamshid S Khorashad, MD, Valeria A De Melo, Heike Fiegler, PhD, Gareth Gerrard, PhD, Dan Brudzevsky, PhD, David Marin, MD, Jane F. Apperley, MBChB, FRCP, FRCPath, John M Goldman, DM, FRCP, FRCPath, Letizia Foroni, MD, PhD, FRCPath, Alistair G Reid, PhD

Blood (2008) 112 (11): 3113.

https://doi.org/10.1182/blood.V112.11.3113.3113

Published: 2008

Journal Articles

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Stephen G O’Brien, MD, PhD, François Guilhot, MD, John M Goldman, DM, FRCP, Andreas Hochhaus, MD, Timothy P Hughes, MD, Jerald P. Radich, MD, Marc Rudoltz, MD, Jeiry Filian, Insa Gathmann, M.Sc., Brian J. Druker, MD, Richard A. Larson, MD

Blood (2008) 112 (11): 186.

https://doi.org/10.1182/blood.V112.11.186.186

Published: 2008

Journal Articles

Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis.

Sinthiya Punnialingam, Hugues de Lavallade, MD, Dragana Milojkovic, MD, Bua Marco, MD, Jamshid S. Khorashad, MD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 2945.

https://doi.org/10.1182/blood.V110.11.2945.2945

Published: 2007

Journal Articles

For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.

Hugues de Lavallade, MD, Jamshid S. Khorashad, MD, Dragana Milojkovic, MD, Simon Wagner, PhD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 323.

https://doi.org/10.1182/blood.V110.11.323.323

Published: 2007

Journal Articles

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Hugues de Lavallade, MD, Dragana Milojkovic, MD, Jamshid S. Khorashad, MD, Alistair Reid, PhD, Eduardo Olavarria, MD, Jaspal Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1045.

https://doi.org/10.1182/blood.V110.11.1045.1045

Published: 2007

Journal Articles

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Hugues de Lavallade, MD, Jamshid S. Khorashad, MD, Marco Bua, MD, Dragana Milojkovic, MD, Eduardo Olavarria, MD, Alistair Reid, PhD, Jaspal S. Kaeda, PhD, John M. Goldman, DM, Jane F. Apperley, MD, David Marin, MD

Blood (2007) 110 (11): 1037.

https://doi.org/10.1182/blood.V110.11.1037.1037

Published: 2007

NARROW

Assessment of Quality of Life in the NCRI Spirit 2 Study Comparing Imatinib with Dasatinib in Patients with Newly-Diagnosed Chronic Phase Chronic Myeloid Leukaemia

Spirit 2: An NCRI Randomised Study Comparing Dasatinib with Imatinib in Patients with Newly Diagnosed CML

Clinical Impact Of Dose Modification On Response To Ponatinib In Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

Ponatinib In Heavily Pretreated Patients With Chronic Phase Chronic Myeloid Leukemia (CP-CML): Management Of Adverse Events (AEs)

Impact Of Baseline (BL) Mutations, Including Low-Level and Compound Mutations, On Ponatinib Response and End Of Treatment (EOT) Mutation Analysis In Patients (Pts) With Chronic Phase Chronic Myeloid Leukemia (CP-CML)

2009 Pandemic Influenza A H1N1 Vaccination In the Patients with Hematologic Malignancies: Requirement for Repeated Dosing to Optimize Seroprotection

KIR2DS1 Genotype Predicts for Cytogenetic Response, Progression-Free Survival and Overall Survival In Patients with Chronic Phase CML on Imatinib

Poor Adherence Is the Main Reason for Loss of CCyR and Imatinib Failure for CML Patients On Long Term Imatinib Therapy.

Efficacy of Tyrosine Kinase Inhibitors (TKIs) as Third Line Therapy In Patients with Chronic Myeloid Leukaemia In Chronic Phase Who Have Failed Two Prior TKIs

BCR-ABL1 Oncogene Down-regulates the Expression of OCT1 in CML.

Long-Term Survival and Late Relapse in 5-Year Survivors of Allogeneic Hematopoietic-Cell Transplantation (HCT) for Chronic Myeloid Leukemia (CML) in First Chronic Phase.

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

T-Cell and B-Cell Responses After Vaccination against Influenza Virus and Pneumococcus in Chronic Phase CML Patients Treated with Tyrosine Kinase Inhibitors.

Epidemiological Study on Survival of Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL) Patients with T315I Mutation. Final Analysis

Common Submicroscopic Genomic Imbalances Accompany the Ph Chromosome at Diagnosis in Chronic Myeloid Leukemia

International Randomized Study of Interferon Versus STI571 (IRIS) 7-Year Follow-up: Sustained Survival, Low Rate of Transformation and Increased Rate of Major Molecular Response (MMR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CMLCP) Treated with Imatinib (IM)

Pleural Effusions Associated with Use of Dasatinib in Chronic Myeloid Leukemia May Have an Auto-Immune Pathogenesis.

For CML Patients in Chronic Phase Who Achieve a Cytogenetic Response to Imatinib the Finding of a BCR-ABL Mutation Predicts for Progression to Advanced Phase but It Has No Such Significance in Primary Resistance.

Outcome, Prognostic Factors and Long-Term Follow-Up in 207 Chronic Phase CML Patients Receiving Front-Line Imatinib 400 mg at a Single Institution.

Long Term Durability of Major Molecular Responses for Patients Treated with Imatinib after Failure of Interferon-Alfa Is Equivalent to That of Patients Achieving Major Molecular Responses to Imatinib as Primary Therapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only